−0.16PLN
−1.85 MPLN
10.05 MPLN
About READ-GENE
Sector
Industry
CEO
Jan Lubinski
Website
Headquarters
Dobra
Employees (FY)
23
Founded
2005
ISIN
PLRADGN00014
FIGI
BBG000KYH0P6
Read-Gene SA engages in the medical research and testing. It develops cancer prevention treatment based on genetic tests. The company was founded on September 27, 2005 and is headquartered in Dobra, Poland.
Trade directly on the supercharts through our supported, fully-verified and user-reviewed brokers.
Frequently Asked Questions
The current price of RDG is 5.54 PLN — it has increased by 0.73% in the past 24 hours.
Depending on the exchange, the stock ticker may vary. For instance, on NEWCONNECT exchange READ-GENE stocks are traded under the ticker RDG.
RDG stock is 5.32% volatile and has beta coefficient of 0.33. Check out the list of the most volatile stocks — is READ-GENE there?
Yes, you can track READ-GENE financials in yearly and quarterly reports right on TradingView.
RDG stock has risen by 8.20% compared to the previous week, the month change is a 13.99% rise, over the last year READ-GENE has showed a 69.42% increase.
RDG net income for the last quarter is −395.66 K PLN, while the quarter before that showed −302.13 K PLN of net income which accounts for −30.96% change. Track more READ-GENE financial stats to get the full picture.
No, RDG doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
Like other stocks, RDG shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade READ-GENE stock right from TradingView charts — choose your broker and connect to your account.
As of Apr 19, 2024, the company has 23.00 employees. See our rating of the largest employees — is READ-GENE on this list?
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So READ-GENE technincal analysis shows the strong buy rating today, and its 1 week rating is buy. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating READ-GENE stock shows the buy signal. See more of READ-GENE technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. READ-GENE EBITDA is −1.02 M PLN, and current EBITDA margin is −10.03%. See more stats in READ-GENE financial statements.